Abstract 363P
Background
Oral cancer is distressing cancer that affects physically and emotionally and is associated with an adverse impact on mental well-being and financial distress. Informal caregivers are a significant source of support to the patient during and after the treatment of cancer patients. Caregiving may become a burden leading to poor quality of life among caregivers. The study intends to evaluate the effect of a patient's financial distress and psychological well-being on the caregiver's health-related quality of life in early vs advanced oral cancer.
Methods
All oral cancer patients treated with curative intent at our institute from September 2019 to March 2022, with a minimum of 6 months follow-up and disease-free, were included in this study, along with the informal caregivers of the patients. Caretakers not suffering from chronically ill and incurable diseases are included in the study. Patients and caregivers were categorised into early-stage (Group A) and advanced-stage (Group B) based on the clinical staging of patients with oral cancer. The patient's financial distress was evaluated using the COST FACIT questionnaire, and Psychological well-being using DASS 21 questionnaire. The quality of life of the caregivers was evaluated using the WHOQOL BREF questionnaire.
Results
A total of 79 patients and their caregivers were included. The median age is 49 among patients and 38 among caregivers. Twenty-one were in Group A; the rest, fifty-eight, were in Group B. It was observed that the patient in group B has Significant financial distress (p<0.05). There was no difference in HRQOL among caregivers of both groups. There was no correlation between financial distress scores and the caregiver's QOL. There was no effect of the patient's psychological well-being on the QOL of caregivers in group A. However, patients with depression in group B had a significant impact on the caregivers' QOL in the psychological (p <0.05) and environmental domains (p <0.05).
Conclusions
The lack of psychological well-being of patients with advanced-stage cancer significantly influences informal caregivers' psychological and environmental quality of life domains.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract